Latest Lion Point Capital, LP Stock Portfolio
Lion Point Capital, LP Performance:
2024 Q3: 1.68%YTD: -37.99%2023: -12.44%
Performance for 2024 Q3 is 1.68%, and YTD is -37.99%, and 2023 is -12.44%.
About Lion Point Capital, LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Lion Point Capital, LP reported an equity portfolio of $44.9 Millions as of 30 Sep, 2024.
The top stock holdings of Lion Point Capital, LP are INSM, GERN, ARDX. The fund has invested 8.5% of it's portfolio in INSMED INC and 6.4% of portfolio in GERON CORP.
The fund managers got completely rid off NEUROCRINE BIOSCIENCES INC (NBIX), ENPHYS ACQUISITION CORP (NFYS) and BURGERFI INTERNATIONAL INC (BFI) stocks. They significantly reduced their stock positions in MARINUS PHARMACEUTICALS INC (MRNS), ARDELYX INC (ARDX) and LUMOS PHARMA INC (LUMO). Lion Point Capital, LP opened new stock positions in BIOHAVEN LTD, BENITEC BIOPHARMA INC (BNTC) and ARCUTIS BIOTHERAPEUTICS INC (ARQT). The fund showed a lot of confidence in some stocks as they added substantially to BLUEBIRD BIO INC, REGENXBIO INC (RGNX) and FENNEC PHARMACEUTICALS INC (FENC).
The top stock holdings of Lion Point Capital, LP are INSM, GERN, ARDX. The fund has invested 8.5% of it's portfolio in INSMED INC and 6.4% of portfolio in GERON CORP.
The fund managers got completely rid off NEUROCRINE BIOSCIENCES INC (NBIX), ENPHYS ACQUISITION CORP (NFYS) and BURGERFI INTERNATIONAL INC (BFI) stocks. They significantly reduced their stock positions in MARINUS PHARMACEUTICALS INC (MRNS), ARDELYX INC (ARDX) and LUMOS PHARMA INC (LUMO). Lion Point Capital, LP opened new stock positions in BIOHAVEN LTD, BENITEC BIOPHARMA INC (BNTC) and ARCUTIS BIOTHERAPEUTICS INC (ARQT). The fund showed a lot of confidence in some stocks as they added substantially to BLUEBIRD BIO INC, REGENXBIO INC (RGNX) and FENNEC PHARMACEUTICALS INC (FENC).
Lion Point Capital, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Lion Point Capital, LP made a return of 1.68% in the last quarter. In trailing 12 months, it's portfolio return was -39.19%.
New Buys
| Ticker | $ Bought |
|---|---|
| biohaven ltd | 1,768,940 |
| disc medicine inc | 378,378 |
| benitec biopharma inc | 358,410 |
| arcutis biotherapeutics inc | 326,430 |
New stocks bought by Lion Point Capital, LP
Additions
| Ticker | % Inc. |
|---|---|
| bluebird bio inc | 132 |
| regenxbio inc | 59.31 |
| fennec pharmaceuticals inc | 26.47 |
Additions to existing portfolio by Lion Point Capital, LP
Reductions
| Ticker | % Reduced |
|---|---|
| marinus pharmaceuticals inc | -67.19 |
| ardelyx inc | -56.81 |
| lumos pharma inc | -56.4 |
| kiniksa pharmaceuticals ltd | -41.35 |
| milestone pharmaceuticals in | -29.32 |
| syndax pharmaceuticals inc | -28.92 |
| insmed inc | -25.78 |
| avadel pharmaceuticals plc | -22.42 |
Lion Point Capital, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| burgerfi international inc | -557,425 |
| burgerfi international inc | -26,251 |
| enphys acquisition corp | -857,813 |
| neurocrine biosciences inc | -1,149,540 |
| battalion oil corp | -24,793 |
Lion Point Capital, LP got rid off the above stocks
Sector Distribution
Lion Point Capital, LP has about 74.5% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 74.5 |
| Others | 25.3 |
Market Cap. Distribution
Lion Point Capital, LP has about 15.3% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 25.3 |
| MICRO-CAP | 24.4 |
| SMALL-CAP | 17.5 |
| MID-CAP | 16.5 |
| LARGE-CAP | 15.3 |
Stocks belong to which Index?
About 59.8% of the stocks held by Lion Point Capital, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 59.8 |
| Others | 40 |
Lion Point Capital, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Lion Point Capital, LP
Lion Point Capital, LP has 23 stocks in it's portfolio. About 43.5% of the portfolio is in top 10 stocks. ARDX proved to be the most loss making stock for the portfolio. MRNS was the most profitable stock for Lion Point Capital, LP last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ARDX | ardelyx inc | 5.68 | 370,000 | 2,549,300 | reduced | -56.81 | ||
| ARQT | arcutis biotherapeutics inc | 0.73 | 35,100 | 326,430 | new | |||
| BATL | battalion oil corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BBIO | bridgebio pharma inc | 2.78 | 49,000 | 1,247,540 | unchanged | 0.00 | ||
| BFI | burgerfi international inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BFI | burgerfi international inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BNTC | benitec biopharma inc | 0.80 | 39,000 | 358,410 | new | |||
| FENC | fennec pharmaceuticals inc | 2.39 | 215,000 | 1,075,000 | added | 26.47 | ||
| GERN | geron corp | 6.37 | 630,000 | 2,860,200 | unchanged | 0.00 | ||
| GOOG | alphabet inc | 0.04 | 100 | 16,719 | unchanged | 0.00 | ||
| INSM | insmed inc | 8.49 | 52,200 | 3,810,600 | reduced | -25.78 | ||
| JSPR | jasper therapeutics inc | 1.34 | 32,000 | 601,920 | unchanged | 0.00 | ||
| LUMO | lumos pharma inc | 0.34 | 39,589 | 153,209 | reduced | -56.4 | ||
| MCRB | seres therapeutics inc | 0.72 | 340,761 | 322,394 | unchanged | 0.00 | ||
| MIST | milestone pharmaceuticals in | 5.60 | 1,654,150 | 2,514,310 | reduced | -29.32 | ||
| MRNS | marinus pharmaceuticals inc | 2.72 | 693,778 | 1,221,050 | reduced | -67.19 | ||
| MSFT | microsoft corp | 0.10 | 100 | 43,030 | unchanged | 0.00 | ||
| NBIX | neurocrine biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NFYS | enphys acquisition corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| RGNX | regenxbio inc | 1.35 | 57,750 | 605,798 | added | 59.31 | ||